Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
Eligible age
10–65 yrs
Accepts
All genders
Locations
33 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
Sponsor: Vertex Pharmaceuticals Incorporated
Where it's recruiting
Alabaster · Birmingham · Fairhope · Huntsville …
Mesa · Phoenix
Little Rock
Fresno · Granada Hills · Los Angeles · Orange …
Bloomfield · Middlebury · New Haven
Washington D.C.
Bay Pines · Bradenton · Brandon · Coral Gables …
Acworth · Atlanta · Augusta · Brunswick …
Chicago · Evergreen Park · Hines · Palos Hills
Fort Wayne · Indianapolis · Mishawaka
Iowa City
Kansas City · Overland Park
Source: ClinicalTrials.gov · NCT05312879 · last updated 2026-08-04